Stock Traders Buy High Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually large options trading on Thursday. Stock traders bought 23,699 call options on the company. This is an increase of approximately 51% compared to the average volume of 15,658 call options.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This represents a 0.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the sale, the director now directly owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here. 15.75% of the stock is currently owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Axxcess Wealth Management LLC increased its stake in Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the last quarter. Wedmont Private Capital raised its holdings in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares in the last quarter. Green Alpha Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 3.6% during the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock worth $454,000 after buying an additional 2,346 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Recursion Pharmaceuticals by 5.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock valued at $346,000 after buying an additional 2,667 shares in the last quarter. Finally, KBC Group NV raised its stake in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock traded down $0.47 on Thursday, hitting $7.46. The stock had a trading volume of 36,540,697 shares, compared to its average volume of 18,155,293. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -4.87 and a beta of 0.86. The business’s 50 day moving average is $7.12 and its two-hundred day moving average is $6.91. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.43) EPS. Analysts forecast that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.